Related Experiment Videos
[Metabolic and vascular risks with oral contraceptives]
1Service endocrinologie et médecine de la reproduction Hôpital, Necker, Paris.
La Revue Du Praticien
|December 1, 1995
Summary
Combined oral contraceptives increase the risk of thrombo-embolic accidents, particularly in women with pre-existing vascular or hemostatic issues. Risk remains low for healthy young women without specific risk factors.
Area of Science:
- Pharmacology and Toxicology
- Vascular Medicine
- Hepatology
Context:
- Combined oral contraceptives (COCs) are widely prescribed hormonal medications.
- Despite formulation changes, COCs are associated with an increased risk of thrombo-embolic events.
- The liver's role in ethinylestradiol metabolism significantly impacts hemostasis.
Purpose:
- To elucidate the mechanism by which COCs affect thrombo-embolic risk.
- To identify patient subgroups at higher risk for vascular complications.
- To evaluate the effectiveness of risk stratification in preventing adverse vascular events.
Summary:
- Ethinylestradiol accumulation in the liver alters the coagulation/fibrinolysis balance, increasing thrombo-embolic risk.
- Individuals with pre-existing arterial/venous wall alterations or hemostatic disorders are at greater concern.
- Risk restriction effectively prevents coronary accidents but shows less efficacy for stroke and venous thrombosis.
Impact:
- Highlights the critical role of hepatic metabolism of COCs in thrombogenesis.
- Emphasizes the importance of screening for underlying vascular and hemostatic risks before prescribing COCs.
- Suggests that while overall vascular events are low in young, healthy women, careful consideration of individual risk factors remains paramount.